Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤ ÀÌÇ༼Æ÷¾Ï¿¡¼­ µ¹¿¬º¯ÀÌÇü p53 ´Ü¹é°ú EGFR mRNAÀÇ ¹ßÇöµµ¿Í ¿¹ÈÄ¿¡ °üÇÑ ¿¬±¸ Pronostic Value of the Expression of Mutant p53 and EGFR mRNA in Transitional Cell Carcinoma of the Bladder

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 4È£ p.663 ~ 672
¼Ò¼Ó »ó¼¼Á¤º¸
¿ÀºÀ·Ä/Bong Ryoul Oh ½ÉÀçÈ«/¹Úâ¼ö/·ù¼ö¹æ/¹Ú¾çÀÏ/Jae Hong Sim/Chang Soo Park/Soo Bang Ryu/Yang Il Park

Abstract

°á·Ð
Á¤»ó ¹æ±¤»óÇÇ 10¿¹¿¡¼­´Â ÀüÇô p53ÀÌ ¹ßÇöµÇÁö ¾Ê¾ÒÀ¸³ª ¹æ±¤ ÀÌÇ༼Æ÷¾Ï¿¡¼­´Â 67¿¹
Áß 31¿¹(43%)°¡ ¹ßÇöµÇ°í EGFRÀº Á¤»ó ¹æ±¤»óÇÇ¿¡¼­´Â 3¿¹¿¡¼­¸¸ ¹ßÇöµÇ¾úÁö¸¸ ¹æ±¤ÀÌÇà
¼¼Æ÷¾Ï¿¡¼­´Â Àü·Ê°¡ ¹ßÇöµÇ¾î ¹æ±¤¾ÏÀÇ ¹ß»ý¿¡ p53À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ¿Í EGFRÀÌ °ü¿©ÇÒ
°¡´É¼ºÀÌ ³ôÀº °ÍÀ¸·Î »ç·áµÇ¾ú´Ù. ¹æ±¤ ÀÌÇ༼Æ÷¾Ï Á¶Á÷ÀÇ p53 ¹ßÇöÀ²Àº ÀÓ»óº´±â¿Í °ü·Ã
ÀÌ ¾ø¾ú°í Ç¥À缺 ¹æ±¤¾Ï¿¡¼­ÀÇ Àç¹ß·ü ¹× ħÀ±¼º ¹æ±¤¾Ï¿¡¼­ÀÇ »ç¸Á·ü°úµµ °ü°è°¡ ¾ø¾úÁö
¸¸ Á¶Á÷ÇÐÀû ºÐÈ­µµ¿Í´Â ÀÇÀÇ°¡ ÀÖ¾ú´Ù. Ç¥À缺 ¹æ±¤¾Ï¿¡¼­ ħÀ±¼º ¹æ±¤¾ÏÀ¸·Î ÁøÇàÇÑ °æ¿ì
¸ðµÎ p53ÀÌ ¾ç¼º ¹ßÇöÀ» º¸¿© p53ÀÌ Á¾¾çÀÇ ÁøÇà¿¡ À־ ÀÇÀÇÀÖ´Â ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î »ç
·áµÇ¾ú´Ù. ±×·¯³ª EGFRÀº ÀÓ»óº´±â, Á¶Á÷ÇÐÀû ºÐÈ­µµ, Ç¥À缺¾ÏÀÇ ÁøÇà ¹× Ä§À±¼º ¾ÏÀÇ »ç
¸Á·ü°ú °ü°è°¡ ¾ø¾ú´Ù. EGFR mRNAÀÇ ¹ßÇöÀ²Àº p53 À½¼º±º°ú ¾ç¼º±º°£¿¡ À¯ÀÇÇÑ Â÷ÀÌ´Â
¾ø¾úÀ¸¸ç p53ÀÌ ¾ç¼ºÀ¸·Î ¹ßÇöµÇ°í µ¿½Ã¿¡ EGFR mRNA°¡ °­¾ç¼º ¹ßÇöµÈ ±ºµµ ´Ù¸¥ ±º¿¡
ºñÇÏ¿© »ç¸Á·ü¿¡ À־ Åë°èÇÐÀûÀ¸·Î ÀÇÀÇÀÖ´Â Â÷ÀÌ´Â ¾ø¾ú´Ù.
#ÃÊ·Ï#
Purpose: We evaluated the correlation between the clinical outcome and the expression
of p53 protein and EGFR mRNA in bladder cancer.
Materials and Methods: Sixty seven patients with transitional cell carcinoma of the
bladder(40 patients with superficial cancer and 27 patients with invasive cancer) and 10
persons with normal urothelium were included in our study. We examined the
overexpression of p53 protein by immunohistochemical analysis and EGFR by in situ
mRNA hybridization. Both expression were compared with the known factors of
prognosis.
Results: Mutant p53 protein was overexpressed in 43.3% of transitional cell carcinoma
cases and undetectable in normal urothelium. The positive staining of EGFR mRNA was
observed in 30% of normal urothelium and 100% of transitional cell carcinoma of
bladder. p53 overexpression was related to the degree of differentiation, but not with the
stage and the recurrence of superficial cancers. Progression to invasive cancer occurred
in 4 patients with superficial cancer and all of them showed p53 protein overexpression,
which had statistical significance(P < 0.05). p53 positivity in invasive cancer was not
related to the poor survival and strong expression of EGFR mRNA. The positive
staining of EGFR mRNA was also not related to stage, grade, recurrence and survival.
When we combined positivity of p53 and EGFR mRNA, we observed that the subset of
patients with strong expression of EGFR mRNA and positive expression of p53 also had
no different survival.
Conclusions: These results suggest that mutant p53 protein does not seem to be a
prognostic marker for the recurrence of superficial cancer and survival but may be a
marker for progression of superficial cancer to invasive cancer.

Å°¿öµå

Bladder tumor; p53; Epidermal growth factor receptor;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS